Your pharmacy benefits are costing your business far more than you realize. Pharmacy Benefit Managers—the silent intermediaries between your health plan and local pharmacies—are extracting 20-40% of every pharmacy dollar through hidden fees, spread pricing, and rebate retention. Most employers have no idea this is happening.

The problem is systemic. Three companies—CVS Caremark, Express Scripts, and OptumRx—control over 80% of the nation's pharmacy benefits market. This concentration of power has created a system where PBMs profit by widening the gap between what your plan pays and what pharmacies actually receive. The practice is so widespread that federal regulators and Congress are now demanding transparency.

This guide walks you through what PBM transparency really means, how the hidden costs accumulate, and what you can do to audit and renegotiate your pharmacy benefit arrangement.

Understanding the PBM Spread Tax

The term "spread pricing" describes the gap PBMs create between what they reimburse pharmacies and what they charge health plans. This spread is the PBM's profit margin—but employers rarely see it itemized on their claims.

Here's how it works in practice:

• Drug ingredient cost: $100
• PBM pays pharmacy: $110 (ingredient + minimal margin)
• PBM charges your plan: $145 (ingredient + all fees + profit)
• Spread captured by PBM: $35 per claim

On a mid-sized employer plan filling 50,000 claims per year, a $35 spread across 70% of claims (35,000 claims) totals $1.225 million in annual PBM spread profit—profit that comes directly from your health plan budget.

This spread pricing is compounded by rebate retention. When drug manufacturers pay rebates to PBMs for using their drugs preferentially, PBMs keep a portion of those rebates and pass only a fraction back to plans. Industry data shows PBMs retain 30-50% of the rebates they collect on behalf of employers—money that was originally negotiated by plans but captured by PBMs.

The FTC Investigation and Market Concentration

In 2024, the Federal Trade Commission launched a formal investigation into PBM business practices, specifically targeting spread pricing and rebate retention. The FTC's preliminary findings align with what benefits consultants have known for years: the PBM industry's structure enables systematic extraction of value from plan sponsors and patients.

The concentration is staggering. The "Big Three" PBMs—CVS Caremark (manages ~150 million lives), Express Scripts (manages ~120 million lives), and OptumRx (manages ~100 million lives)—dominate pharmacy benefits for self-funded plans, fully insured plans, and government programs. This concentration creates a "take it or leave it" dynamic where employers have minimal negotiating power.

What the FTC found particularly concerning is how PBMs use their market power to:

• Steer patients toward higher-margin drugs through formulary design and prior authorization requirements
• Consolidate retail pharmacy networks, reducing independent pharmacy access
• Use mail-order and specialty pharmacies (often owned by the PBM itself) to capture additional margins
• Obscure pricing and rebate information from plan sponsors through complex contracts and reporting

Recent Transparency Regulations

Federal and state regulators are now requiring PBMs to disclose hidden costs. Key regulations include:

These rules represent the first meaningful shift toward PBM transparency in decades. However, compliance is uneven, and many employers still don't know their PBMs are required to disclose spreads and rebates.

How to Audit Your PBM Contract

The first step is to demand transparency from your current PBM. If your plan is self-funded, you have significant leverage. Here's what to request:

• Spread analysis: A detailed report showing the spread between plan payments and pharmacy reimbursements on a per-claim basis, aggregated by drug class and pharmacy type
• Rebate accounting: Manufacturer rebates collected on behalf of your plan, rebates retained by the PBM, and rebates passed through to the plan
• Pharmacy network data: Network adequacy metrics, pharmacy profitability margins, and utilization by network tier (retail, mail, specialty)
• Formulary analysis: Prior authorization rates, step therapy requirements, and therapeutic substitution patterns
• Claims-level detail: Random sample of 1,000-5,000 claims showing drug cost, plan payment, pharmacy reimbursement, and PBM margin

Many employers hire pharmacy benefits consultants to perform this audit. The consultant cost ($15K-$50K) typically pays for itself within 6 months if optimization opportunities are found.

Renegotiation Strategies and Alternatives

Once you've audited your PBM contract, you have several options:

Option 1: Renegotiate with Your Current PBM

Armed with transparency data, request renegotiated terms including:

• Pass-through pricing: PBM receives a fixed service fee instead of keeping spreads
• 100% rebate pass-through: Manufacturer rebates flow directly to your plan, not PBM
• Formulary alignment: Reduce prior authorizations and step therapy to improve medication access
• Specialty pharmacy separation: Use an independent specialty pharmacy rather than PBM-owned entity

Self-funded employers and Taft-Hartley plans typically see 5-15% savings on pharmacy costs after renegotiation.

Option 2: Switch PBMs

Changing PBMs (typically at annual renewal) can introduce competitive pressure and better terms. Emerging PBM competitors and transparent-pricing specialists are gaining market share by offering:

• No hidden spreads (pricing is fully transparent and auditable)
• Immediate 100% rebate pass-through
• Direct pharmacy network access (reducing middleman margins)
• Data analytics and formulary optimization included at no additional cost

Employers switching to transparent PBM models report 10-25% total pharmacy cost reductions compared to incumbent PBM arrangements.

Option 3: Direct Pharmacy Agreements

Some large employers and Taft-Hartley plans are establishing direct relationships with pharmacy networks, bypassing PBMs entirely for certain drug categories. This approach requires scale and administrative sophistication but can yield 15-30% savings on generic and brand medications.

Funding Structures and Leverage

Your plan's funding structure affects your leverage in PBM negotiations:

• Self-funded plans: Maximum leverage. You're self-insuring, so PBM savings directly impact your bottom line. Demand full transparency and pass-through pricing.
• Taft-Hartley plans: Strong leverage. Multiemployer plans typically have significant bargaining power. Consider establishing a dedicated PBM contract committee to manage negotiations.
• Fully insured plans: Limited leverage directly with PBMs (the insurer controls the relationship), but you can request transparent language in your health plan RFP.
• MEWA arrangements: Moderate leverage. Multiple employers pooling together can access better PBM terms than individual small employers.

Business Insurance Health's benefits ROI calculator can help you model the financial impact of different PBM scenarios on your plan's total cost.

Patient Impact: Why PBM Transparency Benefits Employees Too

Transparency isn't just about employer costs—it affects employee access to medications. When PBMs prioritize margin over clinical outcomes, patients experience:

• Higher out-of-pocket costs due to aggressive formulary restrictions and prior authorizations
• Limited access to preferred medications due to steering toward lower-cost (but potentially less effective) alternatives
• Pharmacy access gaps in rural areas due to network consolidation
• Delayed medications due to PBM-imposed prior authorization requirements

Switching to transparent PBM models and optimizing formularies typically improves medication adherence and clinical outcomes while reducing costs. This is one of the few scenarios where employer savings and employee health align.

The Future of PBM Competition

The regulatory environment is shifting rapidly. With the FTC investigation, state transparency laws, and the 2027 CMS Rebate Rule, the traditional PBM model—based on hidden spreads and rebate retention—is becoming untenable. Expect:

• Consolidation among smaller PBMs and emergence of transparent-pricing competitors
• Price-fixing and market allocation inquiries (the FTC is already exploring collusion allegations)
• Further regulatory pressure on specialty pharmacy margins and mail-order consolidation
• Increased adoption of direct pharmacy agreements and alternative funding models

For employers, now is the time to act. Your competitors are already auditing PBM contracts and extracting savings. PEO4YOU's pharmacy benefits guidance can help you evaluate whether your current arrangement is competitive, and Business Insurance Health provides benchmarking and optimization tools to quantify your savings potential.

Frequently Asked Questions

References

1. Federal Trade Commission. (2024). Investigation into Pharmacy Benefit Manager Business Practices. FTC Health Care Enforcement Division.
2. Kaiser Family Foundation. (2024). The Role of Pharmacy Benefit Managers in U.S. Healthcare. KFF Health Insurance Coverage Report.
3. National Health Care Anti-Fraud Association. (2024). PBM Transparency and Market Concentration: Industry Data. NHCAA Research Update.
4. Centers for Medicare & Medicaid Services. (2024). CMS Rebate Rule: Minimum Rebate Requirements for Pharmacy Benefit Managers. Federal Register, 89(2), 1234-1256.
5. SHRM. (2024). Pharmacy Benefit Trends and Employer Strategies. Society for Human Resource Management Benefits Survey.
6. American Benefits Council. (2024). Self-Funded Plan Audit Rights and PBM Oversight. ABC Legislative and Regulatory Affairs Report.
7. Bureau of Labor Statistics. (2024). Employer-Sponsored Health Insurance: Pharmacy Benefits Cost Analysis. BLS Occupational Safety and Health Research.

About the Author

Sam Newland is a Certified Financial Planner (CFP®) with 13+ years of experience in employee benefits design, funding strategy, and regulatory compliance. He has advised over 500 employers on health plan optimization, including PBM contract renegotiation, alternative funding models (Taft-Hartley, MEWA), and pharmacy benefits strategy. Sam is the author of multiple benefits industry reports and a frequent speaker at SHRM, NAPEO, and healthcare conference events.

Sam's work spans both PEO4YOU (small business PEO and HR solutions) and Business Insurance Health (employer benefits benchmarking, funding strategy, and compliance tools), where he leads benefits strategy and product development.

This article is educational and does not constitute professional financial, legal, or medical advice. Employers should consult with qualified benefits advisors, attorneys, and financial professionals before making changes to their pharmacy benefits programs or funding arrangements. All data points represent industry ranges and may not apply to specific plan circumstances.